We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

GSK plc (NYSE:GSK) is focusing on building on its existing portfolio of long-acting HIV ... in new antibiotics and vaccines. Notable products include Gepotidacin, the first completely new ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Germany’s Stada is to expand its over-the-counter business after agreeing to buy a portfolio of consumer health products from GlaxoSmithKline. No financial details of the agreement have been ...

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal ...